Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in Western countries but very rare in Asia. Peripheral blood or bone marrow mononuclear cells obtained at initial diagnosis from 194 patients with CLL were analysed to determine the ethnic difference in genetic abnormalities. Mutated IGHV was detected in 71Á2% of Taiwanese CLL and IGHV3-23 was the most frequently used gene. Stereotyped BCR was present in 18Á3% with subset 8 being the most frequent. All cases with subset 8 belonged to IGHV 4-39 and were exclusively associated with un-mutated IGHV and poor outcome. Mutation frequencies of SF3B1 (9Á7%), NOTCH1 (8Á6%), BIRC3 (1Á1%), ATM (16Á9%) or TP53 (8Á1%), and frequencies of cytogenetic abnormalities including trisomy 12 (18Á6%), del(17p) (10Á4%), del (13q) (43Á7%) and IGH translocation (10Á1%) were comparable to those reported from Western countries, except del(11q) (6Á9%) which was lower in our patients. Patients with un-mutated IGHV, subset 8, disrupted TP53, trisomy 12, and SF3B1 mutations had a worse outcome compared to patients without these mutations. In conclusion, IGHV3-23 usage, stereotyped subset 8 and lower frequency of del(11q) show an ethnicity-dependent association in Taiwanese CLL patients.
Summary
Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in Western countries but very rare in Asia. Peripheral blood or bone marrow mononuclear cells obtained at initial diagnosis from 194 patients with CLL were analysed to determine the ethnic difference in genetic abnormalities. Mutated IGHV was detected in 71Á2% of Taiwanese CLL and IGHV3-23 was the most frequently used gene. Stereotyped BCR was present in 18Á3% with subset 8 being the most frequent. All cases with subset 8 belonged to IGHV 4-39 and were exclusively associated with un-mutated IGHV and poor outcome. Mutation frequencies of SF3B1 (9Á7%), NOTCH1 (8Á6%), BIRC3 (1Á1%), ATM (16Á9%) or TP53 (8Á1%), and frequencies of cytogenetic abnormalities including trisomy 12 (18Á6%), del(17p) (10Á4%), del (13q) (43Á7%) and IGH translocation (10Á1%) were comparable to those reported from Western countries, except del(11q) (6Á9%) which was lower in our patients. Patients with un-mutated IGHV, subset 8, disrupted TP53, trisomy 12, and SF3B1 mutations had a worse outcome compared to patients without these mutations. In conclusion, IGHV3-23 usage, stereotyped subset 8 and lower frequency of del(11q) show an ethnicity-dependent association in Taiwanese CLL patients.
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Chronic lymphocytic leukaemia (CLL) is a disease characterized by the proliferation and accumulation of morphologically mature lymphocytes expressing CD5, CD20 and CD23, together with low expression of surface IgM (Rozman & Montserrat, 1995) . CLL is the most common leukaemia in Western countries (Rozman & Montserrat, 1995; Morton et al, 2006) but its incidence is very low in Asia (Weiss, 1979) . In CLL, mutational status of the immunoglobulin heavy-chain variable (IGHV) gene, which is widely accepted as one of the most reliable predictors of clinical outcome, can be divided into two subgroups with prognostic relevance: mutated IGHV associated with indolent clinical course and un-mutated IGHV, with a progressive disease course even in the patients with early stage disease (Damle et al, 1999; Hamblin et al, 1999; Oscier et al, 2002) .
The reported frequencies of mutated IGHV ranged from 42Á4% to 64Á2% in the West (Duke et al, 2003; Tobin et al, 2004; Agathangelidis et al, 2012) compared to 60~78Á8% in Oriental patients with CLL (Nakahashi et al, 2009; Xia et al, 2015; Marinelli et al, 2016) . In addition to IGHV mutational status, IGHV repertoire analysis showed that IGHV families or IGHV gene usage had geographically biased predispositions. In the West, the most predominant IGHV family was IGHV3 followed by IGHV1 (Hamblin et al, 1999; Duke et al, 2003; Tobin et al, 2004) . In contrast, Asian cohorts were dominated by IGHV3 followed by IGHV4 (Chen et al, 2008; Hojjat-Farsangi et al, 2009; Nakahashi et al, 2009; Marinelli et al, 2016) except in one recent small series study from Taiwan, which described a very low frequency of IGHV4 (Wu et al, 2017) .
Another important characteristic of the IGHV repertoire is the expression of stereotyped B-cell receptors (BCRs). Homologous stereotyped Complementarity-Determining region 3 (CDR3) within BCRs were identified in 20~30% of CLL cases, which has been suggested to be involved in the pathogenesis of CLL and could be subdivided into 19 major subsets and other minor subsets (Stamatopoulos et al, 2007; Agathangelidis et al, 2012; Rani et al, 2016) . Notably, the frequency of the usage of BCR subsets showed great variation among different geographic areas (Marinelli et al, 2016) .
In addition to IGHV mutational status, chromosomal aberrations and gene mutations are other important prognostic markers of CLL. Patients with 17p deletion [del(17p)] had inferior survival whereas those with del(13q) or trisomy 12 had better outcomes, and patients carrying del(11q) had an intermediate survival (Dohner et al, 2000) . CLL patients with TP53, NOTCH1, SF3B1, ATM or BIRC3 mutations had poor prognosis Puiggros et al, 2014) . A substantial difference in the frequencies of gene mutations was observed between Caucasian and Asian patients (Xia et al, 2015) . In the present study, we sought to investigate the untreated diagnostic samples of a larger cohort of CLL patients in Taiwan for the frequencies of IGHV mutational status, IGHV usage, BCR stereotype, chromosomal aberrations and gene mutations, as well as correlate the genetic abnormalities with their outcomes.
Materials and methods

Patients and samples
Between July 1991 and December 2017, 194 patients with CLL were consecutively diagnosed and were regularly followed-up at a single tertiary referral centre in Taiwan. Diagnosis of CLL was based on the International Workshop of CLL-National Cancer Institute (IWCLL-NCI) criteria (Hallek et al, 2008) . All patients met the criteria of ≧ 5 9 10 9 /l monoclonal B cells in the peripheral blood with expression of CD5, CD20 and CD23 by flow cytometry. Peripheral blood or bone marrow mononuclear cells (MNC) were obtained from the diagnostic sample of each patient by Ficoll-Hypaque density gradient centrifugation and freshly frozen at À80°C until testing. The study was approved by the Institutional Review Board of Chang Gung Memorial Hospital (105-1282C).
gDNA extraction, cDNA synthesis, PCR amplification, and sequencing gDNA and total RNA were extracted from peripheral blood or bone marrow MNC and complementary DNA (cDNA) was synthesized. To determine IGHV usage, clonal IGH rearrangements were amplified from cDNA using two primer pairs: (i) seven leader primers and an IgM/IgG primer (Fais et al, 1998) ; (ii) seven leader primers and a JH primer (McCarthy et al, 2003) . In three cases with no cDNA as template, targets were amplified from gDNA. PCR products were purified and sequenced in both directions, and then aligned to the closest matched germline gene by using the IMGT/V-QUEST analysis software (IMGT; http://www.imgt.org/, Montpellier, France). Sequences with a germline identity of 98% or higher were considered un-mutated IGHV, and those with less than 98% identity as mutated IGHV (Hamblin et al, 1999) . The IGHV CDR3 of each sequence was also analysed by IMGT analysis software. For the clustering analysis, sequences were applied to ClustalW2 (http://www.ebi.ac. uk/Tools/msa/clustalw2/) and then successive filtering was carried out on the basis of previously proposed criteria (Darzentas et al, 2010) . All IGHV sequences were also evaluated using the online tool ARResT/AssignSubsets (http://tools.bat.infspire.org/arrest/assignsubsets) (Bystry et al, 2015) . Novel clusters identified in this study but not defined (Agathangelidis et al, 2012) were assigned a number preceded by the word 'Cluster'.
Fluorescence in situ hybridisation in CLL
Locus-specific probes including TP53 (17p13)/MPO (17q22) (Kreatech, Amsterdam, Netherlands) for del(17p), D13S319/ 13q34 (Vysis, Des Plaines, IL, USA) for del(13q), ATM (11q22)/GLI1 (12q13) (Kreatech) for del(11q)/trisomy 12 and IGH breakapart (Vysis) for IGH translocation were used.
Analysis of ZAP70 expression by flow cytometry
Fluorescently labelled antibodies to CD5-peridinin chlorophyll protein (PerCP)-cyanine (Cy) 5Á5 and CD19-allophycocyanin (APC) were obtained from Becton Dickinson (San Jose, CA, USA). ZAP70-Alexa Fluor 488 and Mouse IgG1 Alexa Fluor 488 antibodies were purchased from Caltag (Buckingham, UK). Frozen or fresh MNC were stained by adding CD5-PerCP-Cy5Á5 and CD19-APC, permeabilised with 8E reagent, which was kindly provided by Prof. Dario Campana at National Singapore University, and followed by ZAP70-Alexa Fluor 488 staining. Cells were then analysed with a BD FACS Aria III flow cytometer and FACS Diva Software (Becton Dickinson, San Jose, CA, USA). The percentage of B cells positive for ZAP70 was determined by gating the CD19/CD5 population. The threshold was set at 20%, as described previously (Crespo et al, 2003; Richardson et al, 2006) .
Mutational analysis using next generation sequencing
Ion AmpliSeq primer pools for TP53 (exons 2-11), NOTCH1 (exons 28-34), SF3B1 (exons 11-16), BIRC3 (exons 3-9) and ATM (whole coding exons) were used to amplify the targets. Library was constructed by using Ion AmpliSeq TM Library kit (Life Technologies, Carlsbad, CA, USA) and sequenced on the Ion Torrent PGM (Life Technologies) machine. Mutations were then analysed with the Variant Caller software offered by the Torrent Server. Sanger sequencing or pyroseqencing was used to validate the mutations. free survival (TFS), and until death or end of follow-up, defined as overall survival (OS). All statistical analyses were carried out using the Sigmaplot statistical package (Systat Software Inc., San Jose, CA, USA). Categorical variables were compared using Fisher exact test. Multivariate analysis was done by Cox proportional hazard regression. Survival curves were constructed by Kaplan-Meier estimate and differences were evaluated by log rank test. Two-tailed P values less than 0Á05 were considered as statistically significant.
Results
IGHV usage
Three of 194 patients with no reliable or reproducible clonal IGHV were excluded from IGHV analysis. Based on a cut-off of 2% deviation from the germline sequence, 136 out of 191 patients (71Á2%) had IGHV mutated gene sequences, and the remaining 55 had sequences (28Á8%) that belonged to the un-mutated subgroup. The most frequently expressed IGHV family was IGHV3 (n = 102, 53Á4%), followed by IGHV4 (n = 49, 25Á7%), IGHV1 (n = 26, 13Á6%), IGHV2 (n = 7, 3Á7%), IGHV5 (n = 4, 2Á1%), IGHV6 (n = 2, 1Á0%) and IGHV7 (n = 1, 0Á5%) ( Fig 1A) . For mutational status of IGHV region among the most common IGHV families, the vast majority of IGHV1 expressing-cases showed more unmutated (16/26; 61Á5%) compared to IGHV3 (20/102; 19Á6%, P < 0Á0001) or IGHV4 families (14/49; 28Á6%, P < 0Á0071) ( Fig 1A) . The IGHV mutational status in the most frequent IGHV usage subtypes is shown in Fig 1B. IGHV3-23 (n = 20, 10Á5%) was the most used, followed by IGHV3-7 (n = 18, 9Á4%), IGHV3-74 (n = 14, 7Á3%), IGHV4-59 (n = 13, 6Á8%), IGHV3-30 (n = 12, 6Á3%), IGHV4-34 (n = 11, 5Á8%), IGHV4-39 (n = 11, 5Á8%) and IGHV1-69 (n = 11, 5Á8%). IGHV3-23 (19Á6%), IGHV3-7 (17Á6%) and IGHV3-74 (13Á7%) constituted 51Á0% of all IGHV3 cases, which were highly associated with mutated IGHV status (95Á0%, 94Á4% and 78Á6%). IGHV4-59 (26Á5%), IGHV4-34 (22Á4%) and IGHV4-39 (22Á4%) constituted 71Á4% of all IGHV4-expressing cases, in which mutated cases were 76Á9%, 90Á9%, and 27Á3%, respectively. In the IGHV1 family, IGHV1-69 (42Á3%) was the most frequent IGHV1-expressing subtype with a mutated frequency of 9Á1%.
Stereotyped BCR
Thirty-five of 191 patients (18Á3%) had homologous IGHV CDR3 (stereotyped BCR), 17 of them (8Á9%) were assigned to the seven defined major subsets, i.e. subset 8 (n = 8), subset 1 (n = 3), subset 2 (n = 2), and one each for subset 5, subset 12, subset 14 and subset 77. Thirteen of 17 cases could be assigned to a previously identified subset using ARResT/ AssignSubsets tool (Bystry et al, 2015) . Four sequences belonged to three minor subsets, including subsets 7 (n = 2), 13 (n = 1) and 98 (n = 1), and the remaining seven clusters, which could not be allocated to the known subsets, were numbered as Clusters 1-7 with two each for the seven clusters. Table I shows the subsets or clusters of the 35 patients carrying stereotyped BCR, their IGHV subtypes and mutational status, CDR3 length, and amino acid sequence. Unmutated IGHV gene showed strong association with stereotyped BCR compared with non-stereotyped BCR group (21 of 35 vs. 34 of 156; P < 0Á0001). Clusters 1, 2, 3, 6 and subset 2 were composed mainly of mutated IGHV sequences whereas subsets 1, 7 and 8, and Clusters 5 and 7 were composed of un-mutated sequences. For IGHV CDR3 length, the median amino acid (aa) length of the 191 CLL patients was 14 aa (range: 6-37). Un-mutated IGHV-CLL patients had a significantly longer IGHV CDR3 (median aa: 19, range: 9-37) than mutated IGHV-CLL patients (median aa: 13, range: 6-27) (P < 0Á0001).
Cytogenetic and genetic lesions
Cytogenetic abnormalities were detected in 80 of 183 (43Á7%) for del(13q), 35 of 188 (18Á6%) for trisomy 12, 19 of 183 (10Á4%) for del(17p), 13 of 188 (6Á9%) for del(11q) and 18 of 179 (10Á1%) for IGH translocation. The mutational status of TP53, NOTCH1 and SF3B1 was analysed in 186 patients with a frequency of 8Á1%, 8Á6% and 9Á7%, respectively; 31 of 183 patients (16Á9%) had ATM mutations, and 2 of 183 patients (1Á1%) had BIRC3 mutations. The results of gene mutations in CLL patients are summarized in Fig 2. Of the 183 patients with mutational status available for all 5 genes, 12 patients had 2 concurrent mutations: 5 coexisting SF3B1and ATM mutations; 2 each co-existing SF3B1 and NOTCH1, and ATM and TP53 mutations; one each coexisting NOTCH1 and ATM, NOTCH1 and BIRC3, and SF3B1 and TP53 mutations. NOTCH1 and TP53 mutations were mutually exclusive. The remaining patients had only one mutation. Correlations of gene mutations with cytogenetic abnormalities demonstrated that TP53 mutations were closely associated with del(17p) compared with no del(17p) (42Á1% vs. 4Á4%; P < 0Á0001), and ATM mutations correlated with del(11q) compared with no del(11q) (53Á8% vs. 14Á4%; P = 0Á0019).
Among the gene mutations analysed, SF3B1 mutations were significantly associated with un-mutated IGHV (10 of 52 vs. 7 of 131; P = 0Á0083) and absent for stereotyped BCR subset 8. There was no correlation between mutated genes and ZAP70 > 20% but a higher frequency of un-mutated IGHV in patients with ZAP70 > 20% (P = 0Á0064) was observed: 25 (39Á7%) of the 63 patients with ZAP70 > 20% had un-mutated IGHV compared with 3 (10Á7%) of the 28 patients with ZAP70 ≦ 20% had un-mutated IGHV. Although no correlation of SF3B1, NOTCH1 or TP53 mutations with stereotyped BCR subsets was observed, we found TP53-mutated cases had a higher frequency of IGHV1-69 usage compared with TP53-unmutated cases (3 of 15 vs. 8 of 168; P = 0Á0495). 
Prognostic relevance of cytogenetic/genetic abnormalities
With a median follow-up of 49Á6 months, the median TFS and OS was 24Á4 months [95% confidence interval (CI): 13Á6-35Á2] and 110Á0 months (95% CI: 82Á3-136Á7), respectively. The impact of cytogenetic abnormalities on outcomes was analysed. Patients with cytogenetic lesions had a comparable TFS among all groups (P = 0Á215) or between any two different groups except that patients with trisomy 12 had a shorter TFS than those with del(13q) (median, 19Á4 months vs. 30Á0 months, P = 0Á028). In contrast, there was a significant difference in OS among different cytogenetic groups (P = 0Á001). The median OS of patients with del(13q), del (11q), trisomy 12, del(17p) and normal karyotypes was 154Á6 months, 88Á5 months, 80Á5 months, 44Á3 months and 95Á8 months, respectively. Patients with trisomy 12 had an inferior OS compared to those with del(13q) (P = 0Á0001), or those with normal karyotypes (P = 0Á037). Prognostic impact of the genetic abnormalities in CLL is shown in Table II . By univariate analysis, TFS was significantly shorter in patients with un-mutated IGHV (median, 7Á7 months vs. 36Á2 months; P = 0Á001), subset 8 (median, 5Á1 months vs. 28Á0 months; P = 0Á001), trisomy12 (median, 19Á4 months vs. 27Á7 months; P = 0Á044), TP53 disruption (TP53 mutations and/or 17p deletions) (median, 10Á6 months vs. 30Á0 months, P = 0Á038), SF3B1 mutations (median, 1Á7 months vs. 32Á7 months, P = 0Á001), and ZAP70 > 20% (median, 13Á1 months vs. 84Á5 months, P = 0Á009). OS was significantly worse in patients with unmutated IGHV (median, 63Á0 months vs. 144Á2 months; P < 0Á0001), subset 8 (median, 41Á1 months vs. 114Á4 months; P = 0Á001), trisomy 12 (median, 80Á5 months vs. 153 months; P = 0Á001), negative for del(13q) (median, 88Á1 months vs. 154Á6 months, P = 0Á016), TP53 disruption (median, 44Á3 months vs. 123Á0 months, P = 0Á003) and SF3B1 mutations (median, 58Á0 months vs. 126Á3 months, P = 0Á0001). In multivariate analysis (Table III) , the independent predicators for inferior TFS included SF3B1 mutations [Hazard ratio (HR) = 2Á942, 95% CI: 1Á217-7Á114; P = 0Á017], trisomy12 (HR = 1Á997, 95% CI: 1Á009-3Á951; P = 0Á047), and a borderline level for TP53 disruption (HR = 1Á876, 95% CI: 0Á902-3Á904; P = 0Á092) and ZAP70 > 20% (HR = 2Á070, 95% CI: 0Á984-4Á356; P = 0Á055). Independent predicators for inferior OS included un-mutated IGHV (mutated IGHV: HR = 0Á487, 95% CI: 0Á262-0Á907; P = 0Á023), trisomy 12 (HR = 2Á301, 95% CI: 1Á150-3Á951; P = 0Á007), TP53 disruption (HR = 3Á667, 95% CI: 2Á025-6Á639; P < 0Á0001), SF3B1 mutations (HR = 2Á786, 95% CI: 1Á239-6Á267; P = 0Á013) and at a borderline significant level for BCR subset 8 (HR = 2Á307, 95% CI: 0Á896-5Á938; P = 0Á083) (Table III) .
We divided the patients into four genetic groups based on TP53 disruption and IGHV mutational status. Patients with wild-type TP53 and mutated IGHV had a longer TFS compared to those with TP53 disruption and un-mutated IGHV, those with wild-type TP53 and un-mutated IGHV, and those with TP53 disruption and mutated IGHV (P = 0Á001) ( Fig  3A) . As shown in Fig 3B, patients with wild-type TP53 and mutated IGHV had a superior OS compared with those with wild-type TP53 and un-mutated IGHV (P < 0Á0001). OS of patients with TP53 disruption and mutated IGHV was also significantly different from patients with TP53 disruption and un-mutated IGHV (P = 0Á040). A significant difference was also observed between mutated IGHV patients with and without TP53 disruption (P = 0Á002), and between un-mutated IGHV patients with and without TP53 disruption (P = 0Á005). Patients with wild-type TP53 and mutated IGHV had the longest OS among the four groups (P < 0Á0001).
Discussion
A frequency of 71Á2% mutated IGHV genes in our Taiwanese patients with CLL was comparable with a Japanese study (78Á8%) (Nakahashi et al, 2009 ) and a study from Tianjin, China (75Á3%) (Marinelli et al, 2016) . As shown in Table SI , the frequency of IGHV hypermutation was higher in Asian countries. The distribution of IGHV family usage in our cohort followed an order of IGHV3>IGHV4>IGHV1, which was similar to that observed in other Asian cohorts (Nakahashi et al, 2009; Marinelli et al, 2016) but different from IGHV3>IGHV1>IGHV4 hierarchy in the West (Agathangelidis et al, 2012; Marinelli et al, 2016) . Our findings confirmed that IGHV gene repertoire in CLL is geographically heterogeneous. The present study showed that the frequency of mutated IGHV was higher in IGHV3 and IGHV4 families than that of un-mutated IGHV whereas IGHV1 family carried predominantly un-mutated IGHV, which was in line with the studies of Caucasians (Duke et al, 2003; Karan-Djurasevic et al, 2012; Rani et al, 2016) . Notably, IGHV3-23 was most frequently expressed in the present study and another Taiwanese study (Wu et al, 2017) , which were different from all other Asian countries in which IGHV4-34 was the most frequently expressed gene in Japan and China (Nakahashi et al, 2009; Marinelli et al, 2016) . On the contrary, the most frequently used gene in the Western studies was IGHV1-69 (Agathangelidis et al, 2012; Marinelli et al, 2016) (Table SI) . Based on the stringent criteria for the analysis of stereotype in IGHV CDR3 amino acid sequences (Darzentas et al, 2010) , the expression frequency of stereotyped BCR was lower than those observed in Western studies (Stamatopoulos et al, 2007; Agathangelidis et al, 2012; Marinelli et al, 2016) (18Á3% vs. 25-30%) . The length of IGHV CDR3 in the mutated CLL patients was significantly smaller than that in the un-mutated CLL cases in the present study, as well as in other Asian or Western countries (Bianchi et al, 2010; Agathangelidis et al, 2012; Marinelli et al, 2016; Rani et al, 2016) , suggesting that mutated IGHV and smaller CDR3 length might work together to affect the antibodybinding pocket for antigen. According to the studies listed in Table SI , there was a reverse correlation of the frequency of patients with stereotyped BCR and mutated IGHV. The higher frequency of mutated IGHV might be attributed to the lower frequency of stereotyped BCR in our Taiwanese cohort.
We also observed that the frequency of major subsets of stereotyped BCR was lower in Taiwan and China compared with that in the West. Among the reported 19 major subsets, subset 8 was the most frequent subset in our patients, which was the least frequent subset in the Western cohort (Agathangelidis et al, 2012; Marinelli et al, 2016) . These also supported an ethnicity-dependent association of IGHV usage. In addition, previous studies showed that stereotyped BCRs were of prognostic relevance: subset 1 or 2 was associated with poor outcome in the Western studies (Maura et al, 2011; Strefford et al, 2013; Baliakas et al, 2014; Del Giudice et al, 2014) , whereas patients with subset 4 might not require treatment (Rani et al, 2016) . Both the present study and that reported by Marinelli et al. (2016) observed that patients with subset 8 had an unfavourable survival.
The cytogenetic and mutational analyses were performed at initial diagnosis (untreated samples) in all our patients. The frequencies of cytogenetic abnormalities in the present study were in line with those reported from European descendants with CLL at initial diagnosis, except for del (11q). The incidence of del(11q) (6Á9%) was slightly lower in our series than that in Western studies (10-25%) (Dohner et al, 2000; Amare et al, 2013) . A lower frequency of del (11q) was also observed in a Chinese study (9Á5%) , a Korean study (12Á5%) (Yoon et al, 2014) and another Taiwanese study (11%) (Wu et al, 2017) . These data suggested that del(11q) was relatively lower in Asia compared with that in the West.
The mutation rate of TP53 (8Á1%) in the present study was comparable to 8% of 166 diagnostic CLL samples while the mutation frequency was 15% in 307 CLL patients of all stages in a report from China (Xia et al, 2015) and Western studies (Takahashi et al, 2018; Leeksma et al, 2019) . The frequency of 8Á1% for TP53 mutations was lower than 20Á5% of a small Taiwanese cohort (Wu et al, 2017) . It is plausible that different times of sample collection from untreated patients was one of the major reasons to explain these discrepancies. The relationship among molecular alterations in our study was mostly consistent with the reported data, including that NOTCH1 mutations occurred exclusively without TP53 mutations (Rossi et al, 2012) and un-mutated IGHV was frequently associated with SF3B1 mutations (Xia et al, 2015) . However, more IGHV-mutated patients in our cohort had ZAP70 expression compared with that of reported data (Wiestner et al, 2003) . The higher frequency of more than 70% of IGHV hypermutation in our CLL patients might partly explain the lower correlation between un-mutated IGHV and ZAP70 expression in our cohort. In addition, we also failed to find associations of un-mutated IGHV with TP53 or NOTCH1 mutations (Xia et al, 2015) and the correlation of stereotyped BCR subsets with any gene mutations (Sutton et al, 2016) . Notably, the present result showed that TP53 mutations were especially common in cases using IGHV1-69, suggesting that IGHV usage rather than subsets of stereotyped BCR correlated with gene mutations.
Our patients were consecutively diagnosed and were regularly followed-up in a single institution, a tertiary referral centre; however, in our health care system, every patient could visit the tertiary centre directly without following the referral procedure. As the prevalence of CLL is very low and no standard protocol or guideline was available in the earlier years, it was possible that physicians might give oral alkylating agent (chlorambucil) to asymptomatic patients, making the TFS shorter. We believe that OS, rather than the TFS, is more representative of outcome in our CLL cohort. The survival of our patients was inferior to that reported by previous studies from Western countries (Hamblin et al, 1999; Dohner et al, 2000) , to which we have compared our series with regard to the distribution of clinical stages; no differences were observed. The worse survival and earlier progression of Asian CLL patients were also previously reported from South Asia (India, Pakistan or Bangladesh), China and Taiwan (Gunawardana et al, 2008; Wu et al, 2013; Marinelli et al, 2016) , suggesting that the inferior outcome of the present series compared with that of Western patients might be also attributed to ethnic differences. The underlying mechanisms require further investigation. In agreement with the previous studies, our results showed that patients with del(13q) had the most favourable OS and those with del(17p) had the most unfavourable OS (Dohner et al, 2000; Rossi et al, 2013; Fischer et al, 2016) . However, the results of the impact of del(11q) or trisomy 12 on outcome were conflicting among different series Hernandez et al, 2015; Fischer et al, 2016; Gonzalez-Gascon et al, 2016) . Our results showed that there was no effect on TFS in patients with trisomy 12 or del(11q) but a shorter OS was found in patients with trisomy 12 compared with that of del(11q) patients, and a shorter OS compared with patients without four types of cytogenetic lesions. Three (8Á6%) of the 35 patients with trisomy 12 carried a poor risk factor of BCR subset 8 compared with 5 (3Á3%) of the 150 patients without trisomy 12 carrying BCR subset 8, which might partly explain one of the reasons for the poor outcome of patients with trisomy 12. However, it will be necessary to confirm this association by enrolling more cases with BCR subset 8. In addition, we showed that patients without TP53 disruption and un-mutated IGHV had the longest TFS and OS compared with patients with other groups of different combination of the two unfavourable factors of outcome, which was also reported in other studies (Xia et al, 2015; Fischer et al, 2016) .
To summarise, in a relatively large Taiwanese cohort of CLL, we showed a high frequency of mutated IGHV (71Á2%), low frequency of stereotyped BCR (18Á3%), the most frequent usage of IGHV3-23 gene, lower frequency of del(11q) (6Á9%) and the most frequent stereotyped BCR subset 8. Our results showed that IGHV features and occurrence of del(11q) are ethnicity-dependent associated. In addition, un-mutated IGHV, TP53 disruption, trisomy 12, and SF3B1 mutations were independent predictors for inferior OS.
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